Aspire Biopharma Holdings (ASBP) Total Current Liabilities (2021 - 2026)
Aspire Biopharma Holdings (ASBP) posted quarterly Total Current Liabilities of $3.2 million for Q1 2026, down 68.06% year-over-year from $9.9 million in Q1 2025, and down 58.48% quarter-over-quarter from $7.6 million in Q4 2025.
Aspire Biopharma Holdings (ASBP) Total Current Liabilities (2021 - 2026) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has reported Total Current Liabilities for 6 consecutive years, with $3.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities fell 68.06% year-over-year to $3.2 million; the TTM figure through Mar 2026 stood at $3.2 million (down 68.06% YoY), while the FY2025 annual figure was $7.6 million, up 349.79% from the prior year.
- Total Current Liabilities slipped to $3.2 million in Q1 2026 per ASBP's latest filing, from $7.6 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $13.9 million in Q3 2025 and bottomed at $51756.0 in Q1 2022.
- Historically, Total Current Liabilities has averaged $3.6 million across 5 years, with a median of $1.0 million in 2023.
- Annual changes were most pronounced in 2024 — Total Current Liabilities soared 2094.53% — and 2026, when it sank 68.06%.
- Aspire Biopharma Holdings' Total Current Liabilities stood at $303323.0 in 2022, then surged by 32.97% to $403328.0 in 2023, then jumped by 318.54% to $1.7 million in 2024, then surged by 349.79% to $7.6 million in 2025, then sank by 58.48% to $3.2 million in 2026.
- Business Quant data shows ASBP's Total Current Liabilities at $3.2 million in Q1 2026, $7.6 million in Q4 2025, and $13.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 630.93 Mn |
| 10 | Aspire Biopharma Holdings | 8.30 Mn | -3.86 Mn | -30,086.00 | 1.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.69 Mn |
| Mar 31, 2026 | 3.15 Mn |
| Dec 31, 2025 | 7.59 Mn |
| Sep 30, 2025 | 13.86 Mn |
| Jun 30, 2025 | 10.56 Mn |
| Mar 31, 2025 | 9.87 Mn |
| Dec 31, 2024 | 1.69 Mn |
| Jun 30, 2024 | 6.24 Mn |
| Mar 31, 2024 | 2.63 Mn |
| Dec 31, 2023 | 403,328.00 |
| Sep 30, 2023 | 316,316.00 |
| Jun 30, 2023 | 284,356.00 |
| Mar 31, 2023 | 356,421.00 |
| Dec 31, 2022 | 303,323.00 |
| Sep 30, 2022 | 188,705.00 |
| Jun 30, 2022 | 146,466.00 |
| Mar 31, 2022 | 51,756.00 |
| Dec 31, 2021 | 293,696.00 |